FDA sets July decision date for full approval of Leqembi

The FDA has set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi (lecanemab).

The FDA will hold an advisory committee meeting regarding the application, for which it did not provide a date.